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ABSTRACT
Background: There are problems in diagnosis of allergy to amide-type local anesthetic agents (ALAs), be-
cause definitive diagnosis is not obtained by in vivo tests, which are used for the diagnosis. Consequently, pa-
tients may be exposed to risk. There are few diagnoses based on in vitro tests, and there are almost no rele-
vant studies.
Methods: Authors examined involvement of allergic reaction using the leukocyte migration test (LMT) through
multiple standpoints in 43 patients who underwent suspected diagnosis of allergy to ALAs.
Results: Rate of LMT-positives was 54%, and especially the positive rate of lidocaine hydrochloride prepara-
tions was significantly high. In 15 positives to lidocaine hydrochloride preparations, all cases were indicated as
positive in a test with drugs containing antiseptic agent, but only 3 cases were indicated as positive in a test
with lidocaine hydrochloride alone. In addition, test with paraben was conducted in 4 cases; 2 cases were con-
firmed as positive. In relevance of histories of drug or food allergies, development rates of ALAs-allergies were
the highest in both allergies, and were 35% and 13%, respectively.
Conclusions: There is a high possibility that these adverse reactions were caused by pseudoallergy to drug.
Even by allergic reactions, it was assumed that 80% of them might be caused by antiseptic agents such as
paraben. In addition, it was suggested that ALAs, especially lidocaine hydrochloride preparations have high an-
tigenicity (sensitizing property). Furthermore, it was considered that patients with past history of drug or food al-
lergies have a high potential for manifestation of the reactions.
KEY WORDS
amide-type local anesthetic agents, paraben, past history of allergy, pseudoallergy to drug, the leukocyte mi-
gration test
INTRODUCTION
Local anesthetic agents fall into the general classifica-
tion of ester types and amide types according to their
chemical structures. Regarding adverse reactions
caused by local anesthetic agents, it has been pointed
out that local anesthetic agents may have a risk of al-
lergic responses, since 1920 when contact dermatitis
caused by an ester-type local anesthetic agents was
reported.1 However, reports of adverse reactions de-
creased notably from 1943 when ALAs became used
more frequently at the bedside. Because these types
of drugs have different mechanism of allergy manifes-
tation due to different metabolic pathways,2,3 it is rec-
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ognized that the ALAs have low antigenicity as com-
pared with ester-type agents4,5 and are relatively safe
local anesthetic agents. Nowadays the ALAs are used
widely for various procedures in clinical practice in-
cluding dental treatments, general surgery, and ob-
stetric service. Even though the ALAs became widely
used, however, reports of adverse events were not
eliminated. Various adverse reactions including mild
rash and nausea, and even severe anaphylactic re-
sponse have been reported.6-17
On the other hand, it is known that adverse reac-
tions due to ALAs, which often tend to consider that
apparently it was induced by allergic reactions, may
include reactions caused by patient’s fear of surgical
procedure and administration of anesthetic agent in-
volved in medical practice, manifestation of minor re-
actions mediated by various pharmacological mecha-
nisms, and development of accidental symptoms.18-20
Therefore, cases, which are clinically, generally
called “local anesthetic (mainly amide-type) agent al-
lergy” often include cases that were diagnosed as al-
lergy induced by local anesthetic agents without con-
firming involvement of allergic reaction and without
immunological evidence. Such indeterminate diagno-
sis results in various therapeutic limitations. It actu-
ally creates confusion when administration of local
anesthetic agents becomes required. More specifi-
cally, it is important to conduct examinations to clar-
ify the involvement of allergic reactions in considera-
tion of the fact that hypersensitivity induced by local
anesthetic agents may be caused by not only simple
drug allergy but also minor reaction and accidental
symptoms.
Examination methods used for local anesthetic
agent allergy are mainly challenge test, intradermal
test and patch test, and most of reported cases indi-
cated positive reaction were determined by in vivo
identification tests. The specific IgE-antibody ra-
dioallergosorbent test (RAST), histamine release test
(HRT), basophil activation test (BAT), drug-induced
lymphocyte stimulation test (DLST), and other meth-
ods may be performed in in vitro identification tests.
DLST has been widely used in clinical practice; how-
ever, evidence of clinical efficacy in diagnosis of al-
lergy to local anesthetic agents has not been obtained
yet because of its low detection sensitivity. In other
words, there are almost no valuable studies, which in-
cluded multiple cases analyzed with in vitro identifi-
cation methods in allergy to ALAs.
Authors previously reported that LMT is valuable
as a method to detect and identify responsible agents
for drug hypersensitivity including drug rash.21-25
Potential involvement of a variety of cytokines has
also been reported to date although LMT is not a test-
ing methodology to identify cytokines and chemoki-
nes.26-28 In addition, because LMT has a higher sensi-
tivity than DLST, it is considered that LMT may have
higher detection rate than DLST as in vitro identifica-
tion method.29 Specifically, we recently reported that
a chemotaxis chamber method developed by authors
has an even higher sensitivity than existing agarose
plate method and has a high clinical value.30
Therefore, we examined relationships of the in vi-
tro identification method with hypersensitivity reac-
tion, antigenicity, mechanisms underlying, and past
history of allergy in patients who underwent sus-
pected diagnosis of allergy to ALAs using LMT, a
highly sensitive detection method.
METHODS
SUBJECTS
Patients underwent LMT were 60 suspected patients
of hypersensitivity to ALAs at Suibaragou Hospital,
Japan during the past twenty years (April 1991
through March 2010). Of 60 cases, 17 cases that were
indicated as LMT positive to test drugs other than
ALAs were eliminated. The remaining 43 patients (14
males, 29 females) were included in this study. The
age of patients were ranged from 4 to 94 years old
(under 10 years old, 6 cases; 10’s, 1 case; 20’s, 11
cases; 30’s, 6 cases; 40’s, 4 cases; 50’s, 6 cases; 60’s, 3
cases; 70’s, 5 cases; 80’s, 0 case; and 90’s, 1 case), and
the average age 39.8 ± 23.4 years old (mean ± S.D.).
The purpose of drug administration to the objec-
tives were dental and oral surgical procedure in 32
cases (74%), surgical procedure in 9 cases (21%), and
endoscopic procedure in 2 cases (5%).
Of the subjects, patients with a history of allergy
were 15 cases (29%), including 13 cases (30%) of drug
allergy and 4 cases (9%) of food allergy. In addition, 2
patients (5%) with atopic dermatitis, and 1 patient
(2%) with chronic bronchial asthma were also in-
cluded as allergic diseases. (The numbers of allergic
histories are cumulative.)
The majority of hypersensitivity reactions observed
in the subjects was anaphylaxis including anaphylac-
toid symptoms and shock-like symptoms (25 cases,
66%), followed by 11 cases (29%) of rash, and then 2
cases (5%) of hepatic disorders. Eight of 11 rash
cases were urticaria-type drug eruption. In addition,
there were five suspected cases of drug allergy al-
though these were not clearly diagnosed as hyper-
sensitivity reaction, including nausea due to admini-
stration of anesthesia, in each previous history. Pa-
tient information, such as hypersensitivity reaction
and a period of medication, was obtained from re-
ports about patients who underwent suspected diag-
nosis of drug adverse effect submitted by attending
physicians, medical records, and direct interviews
with patients. All LMT were conducted with sufficient
explanation about the significance of the study, and
consent of the patients. The informed consent was
obtained according to the “Ethical Guidelines for Epi-
demiological Research” of the Ministry of Education,
Culture, Sports, Science and Technology and the
Ministry of Health, Labour and Welfare. The Ethical
Drug Allergies in Local Anesthetics
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Table　1　The suspected drugs in patients with suspected local analgesic agents allergies (Test drugs for leukocyte migration test)
Suspected drugs† Number of cases Incidence (%) Classifi cation by administered purpose (Number of cases)
Lidocaine hydrochloride 39 90.7
Dental and oral operatory (32)
Surgical manipulation (4)
Endoscopy (3)
Propitocaine hydrochloride 18 41.9 Dental and oral operatory (18)
Mepivacaine hydrochloride 14 32.6
Dental and oral operatory (11)
Surgical manipulation (3)
Bupivacaine hydrochloride hydrate  4  9.3 Surgical manipulation (4)
Total 75
†In this table, the same patients are counted in two or more categories in case of suspected drugs.
Committee of Suibaragou Hospital also approved the
implementation of LMT.
TEST (SUSPECT) DRUG
The number of test drugs of 43 subjects was at least 1
drug to at most 10 drugs per case, and 55 types and
171 drugs in all cases, of which drugs for peripheral
nerves was 8 types and 75 drugs. In addition, for
ALAs, lidocaine hydrochloride preparations were 39
cases, propitocaine hydrochloride preparations were
18 cases, mepivacaine hydrochloride preparations
were 14 cases, and bupivacaine hydrochloride hy-
drate preparations were 4 cases as shown in Table 1.
All ALAs used were ethical drugs, and no over the
counter drug (OTC) containing amide-type local an-
esthetic agent was used. The majority of other drugs
were drugs for central nerve, which were 14 types
and 46 drugs, followed by antimicrobial agents,
which were 14 types and 25 drugs, agents affecting
metabolism, which were 5 types and 5 drugs, drugs
for the digestive system, which were 4 types and 5
drugs, and others were 10 types and 15 drugs. (The
numbers of test drugs are cumulative.)
In addition, for 30 of 39 cases tested for lidocaine
hydrochloride preparations, both (two lines) com-
mercialized antiseptic-containing lidocaine hydrochlo-
ride preparations themselves and lidocaine hydro-
chloride alone, which is a main component of the
preparation, were tested separately. Moreover,
methyl parahydroxybenzoate, which is one of inactive
ingredients (antiseptic), was also tested in 4 of 43
cases. No cases, which received a dose in excess of
usual dosage of each drug, were observed.
LMT
Antigen Preparation
Two types of drug antigen solutions were used for
LMT. One antigen solution was prepared by dissolv-
ing bulk powder of each test drug into Hanks’ bal-
anced salt solution (HBSS; Gibco, Grand Island, NY,
USA) and mixing 100 μL of the drug solution with
100 μL of culture medium (10% horse serum [Gibco],
10 mM HEPES buffer added TC-199 medium
[Gibco]) (Antigen solution without patient serum;
control solution was a mixed solution of 100 μL of
HBSS and 100 μL of culture medium). Another anti-
gen solution was prepared by mixing 100 μL of the
drug solution with 100 μL of patient serum (antigen
solution with patient serum; control solution was a
mixed solution of 100 μL of HBSS and 100 μL of pa-
tient serum). Poorly soluble drugs were used by dis-
solving in ethanol or 0.1 N sodium hydroxide solu-
tion, or dissolving in dimethyl sulfoxide (DMSO) and
the diluted with HBSS so that the final concentration
of DMSO becomes 1% or under. Phytohemagglutinin
(PHA), which is a mitogen, was uses at 1 μgmL of
reaction concentration as a positive control to confirm
the responsiveness of the test.
Maximum drug concentration (Cmax) of each test
drug was used as the antigen concentration of the
drug. However, if Cmax of the drug was unknown, a
concentration of 150,000mL and 110,000mL of a
dosage were used for oral and injectable drugs, re-
spectively. The final antigen concentration of all test
drugs was determined based on control studies con-
ducted at several concentration values to confirm that
there was no influence of the drug per se on immune
activity. The drug antigens were prepared on the day
of LMT. It was confirmed that concentrations of sol-
vent and test drugs used do not exert immunological
influence on the responsiveness of LMT induced by
PHA stimulation.
Separation of Mononuclear Leukocytes and Re-
action Culture
LMT was conducted between 7 days and 3 months af-
ter the discontinuation of test drug administration.
The drugs used for treatment of hypersensitivity re-
action and other drugs used after the treatment in-
cluded drugs that exert influence on the responsive-
ness of LMT, and the test was conducted under con-
ditions without influence on immunological capacity
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in this study. For the reaction between the patient
mononuclear leukocytes and test drugs, mononuclear
leukocytes (an intermediate layer) were collected
from heparinized peripheral blood using specific
gravity centrifugal method with Ficoll-Paque solution
(Pharmacia Biotech, Uppsala, Sweden), and the sepa-
rated mononuclear leukocytes after rinsing with
HBSS were suspended into culture medium at a con-
centration of 1.25 × 106 cellsmL. Then, 800 μL of this
mononuclear leukocytes suspension was added to
200 μL of antigen solution, and incubated in an incu-
bator (BNA-111, ESPEC, Osaka, Japan) under 5%
CO2 at 37℃ for 72-96 hours. Supernatant fluid was
separated and stored at -20℃．
Migration Test
Migration test was conducted using an agarose plate
method (from April 1994 to March 2002) and chemo-
taxis chamber method (after April 2002). Heparinized
peripheral blood from normal individuals was mixed
with 14 volume of 5% dextran saline solution, incu-
bated at 37℃ for 40-60 min, and then a leukocyte
layer (supernatant liquid) was collected. Granulo-
cytes (a precipitated layer) were collected from this
supernatant liquid using specific gravity centrifugal
method with Ficoll-Paque solution, contaminating red
blood cells were hemolyzed with a lysing shock
method, and then rinsed with saline solution to obtain
leukocytes for migration test.
For an agarose plat method, leukocytes for migra-
tion test were suspended into previously separated
reaction supernatant at a concentration of 2.5 × 108
cellsmL, and 7 μL of the cell suspension was dis-
pensed into each well (3 mm in diameter) made of
culture medium with 1% agarose on a plate. Then the
plate was incubated in an incubator under 5% CO2 at
37℃ for 24 hours, and the area of leukocyte migra-
tion was measured with an immuno viewer (IM-
MUNO VIEWER-MU, Jokoh, Tokyo, Japan).
For a chemotaxis chamber method, wells in a
lower chamber of a chemotaxis chamber (96-well
Chemotaxis Chamber AB96, Neuro Probe, Gaithers-
burg, USA) were filled with 30 μL of culture medium,
a membrane filter (Polycarbonate Filters PDF 5,
Neuro Probe) was attached on the upper chamber,
and the upper and lower chambers were coupled.
Leukocytes for migration test were suspended into
reaction supernatant at a concentration of 1 × 104
cellsμL. Then, 50 μL of the suspension was dis-
pensed into 4 wells of the upper chamber for each
specimen, and incubated in an incubator under 5%
CO2 at 37℃ for 90 min for migration. Leukocytes at-
tached to the membrane between the upper and
lower chambers were fixed with Diff-Quik fixing solu-
tion (Sysmex, Hyogo, Japan), stained with Diff-Quik
staining solution (Sysmex); and then absorbance was
measured at 490 nm using an immunoreader (Im-
muno Mini NJ-2300, Intermed Japan, Tokyo, Ja-
pan).30
Determination
Determination of agarose plate method was also con-
ducted for normal individuals in a uniform manner.
Migration index (MI) = (Leukocyte migration area in
leukocyte reaction supernatant with patient serum
[antigen solution] Leukocyte migration area in leu-
kocyte reaction supernatant with patient serum with-
out patient serum [control solution]) × 100 of the nor-
mal individuals was calculated, and a normal range
(NR) was defined as the average MI ± 2 SD (n = 6).
MI value of a patient was 115 and above or 85 and
less was considered as positive.
In LMT determination with chemotaxis chamber
method, MI = (Average absorbance of antigen solu-
tion with patient serumAverage absorbance of anti-
gen solution without patient serum) × 100 was calcu-
lated, and positive was defied as when MI value was
60 and below or 150 and over, and significant differ-
ence of p < 0.05 was observed with Student’s t-test for
control group.30
ANALYSIS OF LMT RESULTS IN PATIENTS WHO
UNDERWENT SUSPECTED DIAGNOSIS OF
DRUG HYPERSENSITIVITY TO DRUGS OTHER
THAN ALAs
To examine involvement of allergic reaction and anti-
genicity of ALAs, and relevance of a history of drug
allergy and food allergy, investigation and analysis
were conducted for drugs other than ALAs based on
LMT results implemented by authors during the past
20 years (April 1991 through March 2010). Espe-
cially, LMT positive rate of drugs, which are consid-
ered to induce drug allergy at high frequency21-23,29,30
such as antimicrobial agents, non-steroidal anti-
inflammatory drugs (NSAIDs), and enzyme prepara-
tions, were examined for each drug group. In addi-
tion, a history of drug allergy and food allergy were
also analyzed for each of the above 3 drug groups.
STATISTICAL ANALYSES
Statistical analyses of data were conducted with χ2-
test, Fisher’s exact probability test, and Student’s t-
test. Hazard ratio of below 5% (p < 0.05) was consid-
ered as a significant difference.
RESULTS
LMT RESULTS IN PATIENTS WHO UNDERWENT
SUSPECTED DIAGNOSIS OF DRUG HYPERSEN-
SITIVITY TO ALAs
LMT was implemented with an agarose plate method
in 16 cases, and with a chemotaxis chamber method
in 27 cases. As the results, 23 of 43 cases (15 cases
were positive to only ALAs, 8 cases were positive to
amide-type and other local anesthetic agents) indi-
cated positive reactions and a positive rate was 53%.
Furthermore, in the LMT results by drugs, positive
Drug Allergies in Local Anesthetics
Allergology International Vol 63, No2, 2014 www.jsaweb.jp 271
Fig.　1　The proportions of positive the leukocyte migration 
test, broken down into hypersensitivity symptomatic catego-
ries. †Anaphylaxis, In these cases, contain anaphylaxis-like 
or shock-like symptom.
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Table　2　The proportions of positive the leukocyte migration test, broken down into suspected drug categories in amide-type
local anesthetic agents
Suspected drugs† Number of cases
LMT‡
Incidence (%)
Positive Rate (%) χ2-test
Lidocaine hydrochloride 39 20 51.3
p = 0.0002
p = 0.0160
87.0
Propitocaine hydrochloride 18  0  0  0
Mepivacaine hydrochloride 14  2 14.3  8.7
Bupivacaine hydrochloride hydrate  4  1 25.0  4.3
Total 75 23 30.7
†In this table, the same patients are counted in two or more categories in case of suspected drugs.
‡LMT, The leukocyte migration test (16 cases by agarose plate method, 27 cases by chemotaxis chamber method); LMT-agarose plate
method, the leukocyte migration test by agarose plate method, this test was regarded as positive if the migration indices of the subject pa-
tients or the control patients were above 115 or below 85. ‡LMT- chemotaxis chamber method, the leukocyte migration test by chemotaxis 
chamber method, this test was regarded as positive if the migration indices (M.I.) of the subject patients or the control patients were above 
150 or below 60 and had a signifi cant difference from the M.I. of 4 negative controls (p < 0.05, Student’s t-test).
response was indicated in 20 of 39 cases for lidocaine
hydrochloride preparations, 0 of 18 cases for propito-
caine hydrochloride preparations, 2 of 14 cases for
mepivacaine hydrochloride preparations, and 1 of 4
cases for bupivacaine hydrochloride hydrate prepara-
tions as shown in Table 2. The lidocaine hydrochlo-
ride preparations showed significantly high positive
rate as compared with propitocaine hydrochloride
preparations and mepivacaine hydrochloride prepara-
tions (p < 0.02).
In addition, only 1 amide-type local anesthetic
agent was identified as positive for each case, and no
cases has 2 or more positive drugs in the entire 23
positive cases.
LMT POSITIVE RATE BY DIFFERENT HYPER-
SENSITIVITY REACTIONS TO ALAs
In the LMT results by hypersensitivity reactions 14 of
25 cases for anaphylaxis, 7 of 11 cases for rash, and 1
of 2 cases for hepatic disorders indicated positive re-
action as shown in Figure 1. In addition, 1 of 5 cases
for no clear hypersensitivity symptoms indicated posi-
tive reaction. In addition, 4 of 7 positive cases of rash
were urticaria-type drug eruption.
LMT POSITIVE RATE OF DRUGSWITH ORWITH-
OUT ADDITIVE IN LMT POSITIVE CASES
CAUSED BY LIDOCAINE HYDROCHLORIDE
PREPARATIONS
For 15 of 20 LMT positive cases caused by lidocaine
hydrochloride preparations, test was conducted with
two drugs, a lidocaine hydrochloride preparation con-
taining antiseptic and lidocaine hydrochloride alone,
which is a major ingredient. As shown in Table 3, all
15 cases indicated positive reaction to the lidocaine
hydrochloride preparation containing antiseptic. On
the other hand, only 3 cases indicated positive reac-
tion to the lidocaine hydrochloride alone, and 12
cases were negative.
Hypersensitivity reactions caused by the lidocaine
hydrochloride preparation containing antiseptic in-
cluded 9 cases of anaphylaxis and 3 cases of rash. On
the other hand, the 3 cases of hypersensitivity reac-
tions caused by lidocaine hydrochloride alone in-
cluded 2 cases of rash and 1 case of shock.
RESULTS OF LMT WITH AN ANTISEPTIC AGENT
(METHYL PARAHYDROXYBENZOATE)
Test was conducted using methyl parahydroxybenzo-
ate itself. As the results, positive reaction was ob-
served in 2 of 4 cases. The results of positive 2 cases
are shown in Table 4, one case was a lidocaine hydro-
chloride preparation, and another case was mepiva-
caine hydrochloride preparation.
COMPARISON OF LMT POSITIVE RATES BE-
TWEEN ALAs AND OTHER DRUGS
The number of cases tested for in test drugs other
Saito M et al.
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Table　3　The incidence rate of positive the leukocyte migration test, broken down into suspected drugs with or without preser-
vatives in the 15 patients developed lidcaine hydrochlorise formulations
Suspected drugs†
LMT‡
Number of positive cases Rate (%) Hypersensitivity symptom (cases)
Lidocaine hydrochloride + Preservatives 15 100
Anaphylaxis§ (9)
Rash (3)
Lidocaine hydrochloride only  3  20
Anaphylaxis§ (1)
Rash (2)
†In this table, the same patients are counted in two or more categories in case of suspected drugs.
‡LMT, The leukocyte migration test. §Anaphylaxis, In these cases, contain anaphylaxis-like or shock-like symptom.
Table　4　The incidence rate of positive the leukocyte migration test, broken down into suspected drugs with or without preser-
vatives in the patients developed lidcaine hydrochlorise formulations
Cases LMT†
Age Sex Hypersensitivity symptom Tested drugs
Antigen
concentration (/mL) M.I.
‡ P value,
Student’s t-test Judgment
25 Fe-male Rash
Mepivacaine hydrochloride  2 μg 119.6 0.08686 Negative
Methyl p-hydroxybenzoate 50 ng 237.0 0.00035 Positive
PHA§  1 μg 316.3 0.00002 Positive
38 Fe-male Anaphylaxis
Lidocaine hydrochloride  1 μg 105.4 0.82602 Negative
Methyl p-hydroxybenzoate 50 ng 184.2 0.00239 Positive
PHA§  1 μg 384.2 0.00039 Positive
†LMT, The leukocyte migration test by chemotaxis chamber method. ‡M.I., The migration index.
§PHA, Phytohemagglutinin (migtogen as a positive contorol in the LMT).
than ALAs was 1330 as shown in Figure 2, and 980
cases of them indicated positive reaction, and LMT
positive rate was 74%. On the other hand, LMT posi-
tive rate of the ALAs was 54%. In these results, LMT
positive rate of the ALAs indicated significantly low
value as compared with other drug groups (p =
0.003). In addition, LMT positive rates of different
drug groups were 76% for antimicrobial agents, 66%
for NSAIDs, and 67% for enzyme preparations. These
LMT positive rates of antimicrobial agents and
NSAIDs were significantly high as compared with
LMT positive rate of the ALAs (p < 0.01).
RATES OF DRUG ALLERGY AND FOOD AL-
LERGY IN LMT POSITIVE CASES
Of 23 cases of LMT positive cases induced with
ALAs, patients who had a past history of drug allergy
to any kind of drugs were 8 cases (2 cases to ALAs, 3
cases to antimicrobial agents, 1 case to NSAIDs, and
2 cases to unknown drugs), which accounted for 35%,
as shown in Figure 3. Also, the percentage of patients
with a history of drug allergy in LMT positive patients
groups for antimicrobial agents, NSAIDs and enzyme
preparations were 13%, 17.3% and 30%, respectively.
Antimicrobial agents indicated significant low value
as compared with the ALAs (p = 0.010).
On the other hand, of 23 cases of LMT positive
cases induced with ALAs, patients with a past or cur-
rent history of food allergy were 3 cases (13%) as
shown in Figure 4. Also, the percentage of patients
with a history of food allergy in LMT positive patients
groups for antimicrobial agents, NSAIDs and enzyme
preparations were 6%, 4% and 5%, respectively.
DISCUSSION
ANTIGENICITY OF ALAs
In local anesthetic agents, it has been known that
amide-type drugs have lower antigenicity and are
safer than ester-type drugs; therefore, many amide-
type preparations are used widely. Especially, use fre-
quency of lidocaine hydrochloride preparations is
currently the highest. There are several types of
amide-type preparations and risks causing toxic reac-
tion has been actively studied,31-34 and lidocaine hy-
drochloride are used widely because there are rela-
tively safer as compared with other drugs. However,
there are almost no investigations about risks induc-
ing allergy reactions in terms of difference of anti-
genicity.
In this study results, LMT positive rate of lidocaine
hydrochloride preparations indicated significantly
high value, which was more than 2 times higher, as
Drug Allergies in Local Anesthetics
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Fig.　2　The proportions of positive the leukocyte migration test, broken down into drug 
categories. *Signifi cantly different, χ2-test. †Total drugs, These tested agents were exclud-
ed amide-type local anesthetics. ‡NSAIDs, Non-steroidal anti-infl ammatory drugs.
73.7 75.8
65.6 67.2
53.5
100
90
80
70
60
50
40
30
20
10
0
Total drugs†
(n = 1330)
Antimicrobial
agents
(n = 393)
NSAIDs‡
(n = 256)
Enzyme
preparations
(n = 64)
Amide-type local
anesthetic agents
(n = 43)
P
os
iti
ve
 r
at
e 
(%
)
p = 0.002*
p = 0.003*
p = 0.006*
p = 0.153*
Fig.　3　The proportions of patients with drug allergic history, broken down into drug cate-
gories in positive cases by the leukocyte migration test. *Signifi cantly different, Fisher’s ex-
act probability test. †NSAIDs, Non-steroidal anti-infl ammatory drugs.
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compared with other propitocaine hydrochloride
preparations and mepivacaine hydrochloride prepara-
tions. Therefore, it is suggested that lidocaine hydro-
chloride preparations may have the highest antigenic-
ity or sensitizing property, and thus have a high risk
to induce allergy symptoms in ALAs. For lidocaine
hydrochloride preparations, there are reports about
contact dermatitis35,36; however, it is considered that
such reports are reflect not its high antigenicity but a
high risk to induce allergy symptoms, because and
use frequency of lidocaine hydrochloride prepara-
tions is currently the highest, for example lidocaine
hydrochloride preparations are contained in some
OTC drugs. Therefore, detailed studies including dif-
ference of antigenicity of each drug in terms of the
chemical structure would be required to prevent sec-
ondary hypersensitivity reactions caused by cross-
over reaction, etc.
INVOLVEMENT OF HYPERSENSITIVITY REAC-
TIONS AND ALLERGIC REACTIONS IN ALAs
Immediate allergy-like symptoms, such as anaphy-
Saito M et al.
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Fig.　4　The proportions of patients with food allergic history, broken down into drug cate-
gories in positive cases by the leukocyte migration test. *Signifi cantly different, Fisher’s ex-
act probability test. †NSAIDs, Non-steroidal anti-infl ammatory drugs.
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laxis, are especially seen as a problem among previ-
ous reports on harmful symptoms caused by ALAs.
Occurrence of immediate allergy-like symptoms is
extremely low, but these symptoms may cause clini-
cal confusion. In symptoms occurred in patients who
underwent suspected diagnosis of hypersensitivity in
this study, anaphylaxis and rash accounted for 95% of
the entire symptoms except unknown cases. Espe-
cially, anaphylaxis accounted for 66% of the entire
symptoms. In addition, 8 of 11 patients with rash de-
veloped rush classified into urticaria-type drug erup-
tion. More specifically, it is considered that there is a
high likelihood that symptoms of most cases were de-
veloped by a mechanism of type I allergy or immedi-
ate allergy, in which Th2 is strongly involved in
helper T cells (Th). Considering that 4 of 7 LMT posi-
tive cases of rush were urticaria-type drug eruption,
hypersensitivity reactions, including anaphylaxis, in-
volved with immediate allergy were detected in 78%
of 23 positive cases as a result. In other words, it is
also suggested that the risk of developing delayed al-
lergy may be about 20%. Only ethical drugs were ex-
amined in this study; however, it is expected that oc-
currence of delayed allergy would become increased
in view of contact dermatitis cases due to OTC drugs
containing ALAs.
When considering about a possibility of induction
due to involvement of allergic reactions, LMT positive
rate of ALAs is only 54%, which is about 20% lower
value as compared with the entire groups of other
drugs, and this is by no means high value. LMT can
detect both types of drug allergies, immediate allergy
and delayed allergy. Previously, authors reported that
LMT indicated 73% of detection performance in pa-
tients who underwent suspected diagnosis of immedi-
ate anaphylactic shock, and that the test was not influ-
enced by (allergy type) hypersensitivity reaction.30
Therefore, it is suggested that detection with LMT in-
dicates specifically low detection rate for ALAs re-
gardless of the development mechanism of allergy.
More specifically, it is also suggested in this study
that it is highly likely that there are many cases in-
duced by mechanisms other than immune response
as “pseudoallergy to drug” even if the patient pre-
sented allergy-like symptoms on the surface.
For allergic symptoms caused by ALAs, there were
many reports that suggested potential pseudoallergy
to drugs. However, most of these diagnoses were
based on in vivo examinations, such as challenge test
and intracutaneous test, and examples of in vitro vali-
dation are extremely poor. Although there is a report
that positive results were obtained with DLST,37
Suzuki et al.38 conducted DLST in 9 cases and re-
ported that all cases were indicated as negative, and
concluded that diagnosis with DLST was invalidity for
ALAs. DLST has a problem of false-positive result and
many questions, but is a useful test for delayed al-
lergy; therefore this is not suitable for elucidation of
the mechanism of local anesthetic agent allergy.29,39
Moreover, there is no report verified using histamine
release test. Therefore, it is considered that our re-
search results using LMT is highly useful, and there
are many hypersensitivity reactions that are not
caused by allergic reactions. Although LMT is not
able to identify the produced cytokines and chemoki-
nes; however, further research would be required to
show involvement of immune reaction through analy-
sis at a cytokine level. In addition, it was considered
that it is clinically important to verify IgE values and
eosinophil counts in the peripheral blood at the same
Drug Allergies in Local Anesthetics
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time although it was not included in this study.
Development of hypersensitivity reactions based
on non-allergic mechanism may include psychogenic
response and vasovagal reflex. Especially, there is a
report that about 80% of patients who underwent sus-
pected diagnosis of allergy to local anesthetic agents
at dental treatment may be caused by vasovagal re-
flex.19 In either case, further detailed studies would
be required in the future, and especially studies to
conduct in vitro examination are also sought in terms
of patient safety.
INVOLVEMENT OF ANTISEPTIC ADDITIVES IN
ALAs
Allergy to parabens and sodium pyrosulfite that are
contained as antisepsis of ALAs has already been re-
ported.40-42 Based on these reports and so forth, it is
becoming popular to use products containing no anti-
septics. In our study results, in examination of 15 of
20 cases that indicated LMT positive with lidocaine
hydrochloride preparations, antisepsis containing
tests indicated 100% of positive reaction. However,
test with lidocaine hydrochloride alone, which con-
tained no antisepsis, indicated only 20% of positive re-
action. In other words, it is suggested that 80% of ac-
tual amide-type local anesthetic agent allergy, in
which involvement of not pseudoallergy to drug but
allergic reaction was confirmed from LMT results,
was induced by not lidocaine hydrochloride itself but
antiseptic. Therefore, in amide-type local anesthetic
agent allergy, it is considered that the percentage of
involvement of antiseptic is high except for pseu-
doallergy to drug, and the amide-type local anesthetic
agent itself, which is a main ingredient, has much
lower antigenicity than that of antiseptic, about 15 of
that of antiseptic.
In addition, although these were data from only 2
cases, it is obvious that antiseptic involves in the
amide-type local anesthetic agent allergy when con-
sidering the cases that LMT strong positive was actu-
ally indicated to methyl parahydroxybenzoate di-
rectly.
Because most of allergy reports caused by paraben
additives are contact dermatitis, it is more likely that
establishment of sensitization is caused by use of
daily commodities such as cosmetics and hairdress-
ings. In other words, it is suggested that there are
risks that allergy is suddenly induced even if the pa-
tient use the ALAs for the first time because of estab-
lishment of sensitization due to use of daily commodi-
ties, even if a patient has no previous use experience
of ALAs. Based on these results, therefore, it is con-
sidered that administration of preparation containing
no antiseptics is desired regardless of previous his-
tory of allergy if at all possible.
RELATIONSHIPS BETWEEN THE AMIDE-TYPE
LOCAL ANESTHETIC AGENT ALLERGY AND
PAST HISTORY OF ALLERGY
For relationships between the amide-type local anes-
thetic agent allergy and past history of allergy, the
risk of developing drug allergy is higher in patients
with a past history of drug allergy than in patients
without the history, as was expected. In our analysis
using LMT, it was reported that development rate of
drug allergy was about 0.3-0.4% in patients without a
past history of drug allergy; meanwhile, development
rate of drug allergy was about 7.6-8.8% in patients
with a past history.21 Hence, about 20 times higher
development risk is suggested for patients with a past
history of drug allergy as compared with patients
without the history. According to results from this
study, especially ALAs indicated high development
rate of 34.8% among them, which was about 3 times
higher than antimicrobial agents, which have high
development rate of drug allergy, and about 2 times
higher than NSAIDs. More specifically, it is sug-
gested that there is a possibility that drug allergy
could be induced in 1 of 3 patients with a past history
of drug allergy. Therefore, it is required to exercise
adequate caution for use of ALAs. Of 8 LMT positive
cases with a past history of drug allergy, lidocaine hy-
drochloride preparations were re-administered in 2
cases. Hence, traditional diagnosis with in vitro ex-
aminations such as LMT would be desired even when
administration in cases, in which a past history of al-
lergy caused by amide-type local anesthetic agent,
was diagnosed as pseudoallergy to drug, or challenge
test are required.
In relationship between past history of drug allergy
and food allergy, ALAs indicated more than 2 times
higher values as compared with antimicrobial agents
and NSAIDs, and it was indicated that there is a ten-
dency development rate caused by the amide-type lo-
cal anesthetic agent is high as compared with other
drugs. Moreover, of 3 patients with allergic diseases,
both of 2 patients with atopic dermatitis presented
LMT positive. Based on these results, it is suggested
that drugs, especially ALAs, have high risks of allergy
development in patients with overall allergic ten-
dency to any of drugs, foods, and diseases.
It is said that amide-type local anesthetic agent al-
lergy is very rare. However, it is considered that fur-
ther studies are required in the future, because re-
cently a number of not only ethical drugs but also
OTC drugs with ALAs have been commercialized,
there is possibility that use of daily commodities may
cause sensitization because antiseptics also contrib-
ute to the sensitization due to its antigenicity at high
rates, and the number of patients with allergy or aller-
gic tendency is increasing.
Diagnosis of hypersensitivity to ALAs is difficult in
many cases; however, it is required to give the high-
est priority to use formulations containing no antisep-
Saito M et al.
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tics and to pay special attention to administration to
patients with a history of allergy, in terms of proper
usage of ALAs with consideration for safety aspect.
Moreover, it is desirable as in the past to administer
ALAs at concentration as low as possible in light of in-
duction of the hypersensitivity based on the non-
allergic mechanism.
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